Prognostic role of miR-9 expression in various human malignant neoplasms: A meta-analysis

OncoTargets and Therapy

Volumn 9, Issue , 2016, Pages 3039-3047

  Liu, Xiao Dan ^a   Luo, Zi Yan ^a   Peng, Hong Xia ^a   Jiang, Hua ^a   Xu, Ling ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Malignant neoplasms; Meta analysis; MicroRNA 9; Overall survival; Prognosis

Indexed keywords

MICRORNA 9;

ADULT; APOPTOSIS; CANCER PROGNOSIS; CANCER SURVIVAL; CELL MOTILITY; CELL PROLIFERATION; FEMALE; HUMAN; LEUKEMIA; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; META ANALYSIS; OVERALL SURVIVAL; PUBLISHING; QUALITY CONTROL; REVIEW; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

EID: 84971328500     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S98923     Document Type: Review

References (52)

1. Acunzo M, Romano G, Wernicke D, Croce CM. MicroRNA and cancer – a brief overview. Adv Biol Regul. 2015;57:1–9.
2. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2015;116(2):281–297.
3. Brooks SA, Blackshear PJ. Tristetraprolin (TTP): interactions with mRNA and proteins, and current thoughts on mechanisms of action. Biochim Biophys Acta. 2013;1829(6–7):666–679.
4. Ma F, Liu X, Li D, et al. MicroRNA-466l upregulates IL-10 expression in TLR-triggered macrophages by antagonizing RNA-binding protein tristetraprolin-mediated IL-10 mRNA degradation. J Immunol. 2010;184(11):6053–6059.
5. Huang L, Lin JX, Yu YH, et al. Downregulation of six microRNAs is associated with advanced stage, lymph node metastasis and poor prognosis in small cell carcinoma of the cervix. PLoS One. 2012; 7(3):e33762.
6. Chen P, Zhao X, Ma L. Downregulation of microRNA-100 correlates with tumor progression and poor prognosis in hepatocellular carcinoma. Mol Cell Biochem. 2013;383(1–2):49–58.
7. Liu R, Chen X, Du Y, et al. Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Clin Chem. 2012;58(3):610–618.
8. Gao W, Lu X, Liu L, et al. MiRNA-21: a biomarker predictive for platinum-based adjuvant chemotherapy response in patients with non-small cell lung cancer. Cancer Biol Ther. 2012;13(5):330–340.
9. Yuva-Aydemir Y, Simkin A, Gascon E, Gao FB. MicroRNA-9: functional evolution of a conserved small regulatory RNA. RNA Biol. 2011; 8(4):557–564.
10. Xu SH, Yang YL, Han SM, Wu ZH. MicroRNA-9 expression is a prognostic biomarker in patients with osteosarcoma. World J Surg Oncol. 2014;12:195.
11. Cai L, Cai X. Up-regulation of miR-9 expression predicate advanced clinicopathological features and poor prognosis in patients with hepatocellular carcinoma. Diagn Pathol. 2014;9(1):1000.
12. Zhu M, Xu Y, Ge M, Gui Z, Yan F. Regulation of UHRF1 by miR-9 modulates colorectal cancer cell proliferation and apoptosis. Cancer Sci. 2015;106(7):833–839.
13. Lu J, Luo H, Liu X, et al. miR-9 targets CXCR4 and functions as a potential tumor suppressor in nasopharyngeal carcinoma. Carcinogenesis. 2014;35(3):554–563.
14. Mohammadi-Yeganeh S, Mansouri A, Paryan M. Targeting of miR9/ NOTCH1 interaction reduces metastatic behavior in triple-negative breast cancer. Chem Biol Drug Des. 2015;86(5):1185–1191.
15. Zhou X, Marian C, Makambi KH, et al. MicroRNA-9 as potential biomarker for breast cancer local recurrence and tumor estrogen receptor status. PLoS One. 2012;7(6):e39011.
16. Ye M, Du YL, Nie YQ, et al. Overexpression of activated leukocyte cell adhesion molecule in gastric cancer is associated with advanced stages and poor prognosis and miR-9 deregulation. Mol Med Rep. 2015; 11(3):2004–2012.
17. Inoue T, Iinuma H, Ogawa E, Inaba T, Fukushima R. Clinicopathological and prognostic significance of microRNA-107 and its relationship to DICER1 mRNA expression in gastric cancer. Oncol Rep. 2012; 27(6):1759–1764.
18. Mitra R, Edmonds MD, Sun J, et al. Reproducible combinatorial regulatory networks elucidate novel oncogenic microRNAs in non-small cell lung cancer. RNA. 2014;20(9):1356–1368.
19. Kang HW, Crawford M, Fabbri M, et al. A mathematical model for microRNA in lung cancer. PLoS One. 2013;8(1):e53663.
20. Emmrich S, Katsman-Kuipers JE, Henke K, et al. miR-9 is a tumor suppressor in pediatric AML with t(8;21). Leukemia. 2014;28(5): 1022–1032.
21. Chen P, Price C, Li Z, et al. miR-9 is an essential oncogenic microRNA specifically overexpressed in mixed lineage leukemia-rearranged leukemia. Proc Natl Acad Sci U S A. 2013;110(28):11511–11516.
22. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
23. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560.
24. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–634.
25. Slattery ML, Herrick JS, Mullany LE, et al. An evaluation and replication of miRNAs with disease stage and colorectal cancer-specific mortality. Int J Cancer. 2015;137(2):428–438.
26. Weidner H, Bill M, Schmalbrock L, et al. High expression of Mir-9 down-regulates the poor outcome prognosticator ERG and associates with reduced relapse-rates in acute myeloid leukemia. Blood. 2014;124:21.
27. Wu S, Jia S, Xu P. MicroRNA-9 as a novel prognostic biomarker in human laryngeal squamous cell carcinoma. Int J Clin Exp Med. 2014; 7(12):5523–5528.
28. Gwak JM, Kim HJ, Kim EJ, et al. MicroRNA-9 is associated with epithelial-mesenchymal transition, breast cancer stem cell phenotype, and tumor progression in breast cancer. Breast Cancer Res Treat. 2014; 147(1):39–49.
29. Fei D, Li Y, Zhao D, et al. Serum miR-9 as a prognostic biomarker in patients with osteosarcoma. J Int Med Res. 2014;42(4):932–937.
30. Xu T, Liu X, Han L, et al. Up-regulation of miR-9 expression as a poor prognostic biomarker in patients with non-small cell lung cancer. Clin Transl Oncol. 2014;16(5):469–475.
31. Zhao Y, Jia H, Dong Q, et al. Prognostic relevance of a metastasis associated miRNA signature for patients with HBV-related early stage hepatocellular carcinoma. Langenbecks Arch Surg. 2014;399:3(390).
32. Sugita F, Maki K, Nakamura Y, Sasaki K, Mitani K. Overexpression of MIR9 indicates poor prognosis in acute lymphoblastic leukemia. Leuk Lymphoma. 2014;55(1):78–86.
33. Wu Z, Wang L, Li G, et al. Increased expression of microRNA-9 predicts an unfavorable prognosis inhuman glioma. Mol Cell Biochem. 2013;384(1–2):263–268.
34. Sun C, Li N, Yang Z, et al. miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition. J Natl Cancer Inst. 2013;105(22):1750–1758.
35. Faria AM, Mariani BMP, Ribeiro TC, et al. A prognostic role of mIR-9 and mIR-30C microRNAs in adult metastatic adrenocortical cancer through LIN28 post-transcriptional repression. Endocr Rev. 2013;34:3.
36. Pignot G, Cizeron-Clairac G, Vacher S, et al. microRNA expression profile in a large series of bladder tumors: Identification of a 3-miRNA signature associated with aggressiveness of muscle-invasive bladder cancer. Int J Cancer. 2013;132(11):2479–2491.
37. Sun SM, Nowek K, Bullinger L, et al. Prognostic and functional relevance of aberrant microrna-9/9* expression in acute myeloid leukemia. Blood. 2012;120:21.
38. Maki K, Yamagata T, Sugita F, et al. Aberrant expression of MIR9 indicates poor in acute myeloid leukaemia. Br J Haematol. 2012;158(2): 283–285.
39. Díaz-Beyá M, Navarro A, Diaz T, et al. The expression pattern of microRNAs (miRNA) might add relevant prognostic information to molecular categorization of intermediate risk cytogenetic acute myeloid leukemia. Haematologica. 2011;96(Suppl 2):23.
40. Song Y, Li J, Zhu Y, et al. MicroRNA-9 promotes tumor metastasis via repressing E-cadherin in esophageal squamous cell carcinoma. Oncotarget. 2014;5(22):11669–11680.
41. Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res. 2006;34:D140–D144.
42. Oom AL, Humphries BA, Yang C. MicroRNAs: novel players in cancer diagnosis and therapies. Biomed Res Int. 2014;2014:959461.
43. Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A. 2004;101(9):2999–3004.
44. Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006;103(7):2257–2261.
45. Berardi E, Pues M, Thorrez L, Sampaolesi M. MiRNAs in ESC differentiation. Am J Physiol Heart Circ Physiol. 2012;303:H931–H939.
46. Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring, and therapeutics. A comprehensive review. EMBO Mol Med. 2012;4(3):143–159.
47. Roy S, Sen C. MiRNA in wound inflammation and angiogenesis. Microcirculation. 2012;19(3):224–232.
48. Krichevsky AM, Sonntag KC, Isacson O, Kosik KS. Specific microRNAs modulate embryonic stem cell-derived neurogenesis. Stem Cells. 2006;24(4):857–864.
49. Laios A, O’Toole S, Flavin R, et al. Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mol Cancer. 2008;7:35.
50. Lujambio A, Calin GA, Villanueva A, et al. A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci U S A. 2008;105(36):13556–13561.
51. Khew-Goodall Y, Goodall GJ. Myc-modulated miR-9 makes more metastases. Nat Cell Biol. 2010;12(3):209–211.
52. Guo LM, Pu Y, Han Z, et al. MicroRNA-9 inhibits ovarian cancer cell growth through regulation of NF-kappaB1. FEBS J. 2009;276(19): 5537–5546.